Accuray (NSDQ:ARAY) said it inked a deal with RaySearch Laboratories to allow Accuray to co-market RaySearch’s RayCare oncology information system in several designated major radiation therapy markets RayCare is designed to handle logistical challenges present in modern radiation therapy centers by using high-performance radiation therapy algorithms, Sunnyvale, Calif.-based Accuray said. “In today’s complex healthcare environment it is […]
Radiosurgery/Radiation therapy
ViewRay reels in $50m debt round
ViewRay said today that it reeled in a debt round worth $50 million from CRG for its MRIdian MRI-guided radiation therapy device, a few months after scrapping an initial public offering that would have fetched $52 million at the midpoint. The debt funding, from healthcare investment firm CRG, consists of an initial $30 million, 3-year, interest-only debt […]
Augmenix touts publication of pivotal SpaceOar study
Augmenix said last week that a pivotal study of its SpaceOar system was published online in the International Journal of Radiation Oncology•Biology•Physics. The 222-patient pivotal study was designed to evaluate safety and efficacy of the SpaceOar System in men undergoing prostate radiotherapy, the company said. The SpaceOar is designed to separate the prostate from the rectal wall during radiation […]
Varian books $87m order on Maryland proton therapy center
ViewRay rescinds $52m IPO
ViewRay yesterday became the latest medical device company to scrap an initial public offering, withdrawing a flotation that would have raised $52 million for its MRI-guided radiation therapy technology.
Report: ViewRay tables $52m IPO
ViewRay postponed its initial public offering with which it planned to raise $52 million for its MRI-guided radiation therapy technology, Renaissance Capital reported.
Oakwood Village, Ohio-based ViewRay had planned to float 4 million shares at $12 to $14 apiece.
ViewRay sets $52m IPO terms
ViewRay today set the terms for its pending initial public offering, saying it plans to float 4 million shares at $12 to $14 apiece.
At the midpoint of the range, the MRI-guided radiation therapy maker’s IPO would fetch $52 million.
Varian to expand in Atlanta, adding 100 jobs
ViewRay registers for $69m IPO
ViewRay last week said it plans to raise up to $69 million in an initial public offering for its MRIdian system, which it bills as "the 1st and only MRI-guided radiation therapy system that images and treats cancer patients simultaneously."